About Us

Getinge provides hospitals and Life Science institutions with products and solutions that aim to improve clinical outcomes and optimize workflows. The offer includes products and solutions for intensive care, cardiovascular surgery, operating rooms, sterile handling and the Life Science sector. Getinge has more than 10,000 employees around the world and products are sold in about 135 countries.


  • Jeanette Hedén Carlsson

    Executive Vice President Communications & Brand Management

    +46 10 335 1003
  • Getinge
    Box 8861, 402 72 Göteborg
    +46 10 335 00 00
  • Links


    The driving force is the same as Getinge’s brand promise – Passion for Life. When we enter the field this is what we carry with us inside.
    Madhuseguntha Durairaj
    I have always been proud of what I do, but the personal connection to the medicines and vaccines our bioreactors help to develop, is much stronger after my own experiences. They help bringing science to life.
    Edwin van der Ree
    It is a very severe situation and we are all exhausted but we keep on going to save more lives.
    Iram Fathema
    During the COVID-19 pandemic we have developed several new ways to virtually interact with our customers.
    Carsten Blecker, Chief Commercial Officer at Getinge.
    The COVID-19 pandemic and the heightened awareness of respiratory health has driven the need for personalized ventilation solutions for critically ill patients. Now more than ever, options for personalized lung protection and personalized weaning solutions are at the forefront of respiratory patient health. Getinge strives to support clinicians and patients by optimizing lung protection and delivering solutions for personalized ventilation.
    Eric Honroth, President, Getinge North America
    More and more of our customers are heading towards a situation in which managing record-long waiting lines for surgeries is as challenging as COVID-19.
    Mattias Perjos, President & CEO at Getinge
    When I arrived at work one of those first traumatic days, I almost couldn’t get through the crowded hallways.
    Dana Yamini
    We are very pleased to offer this optimized and cost effective solution for bioreactor preparation in a time when a lot of research focus is dedicated to vaccine development and production.
    Harald Castler, President Life Science at Getinge.
    I feel very proud that we have managed to keep up the close collaboration with our customers despite all restrictions the pandemic imposed on us in 2020
    Mattias Perjos, President & CEO at Getinge
    Getinge’s brand promise ‘Passion for Life’ also covers the lives of our employees. Also beyond COVID-19, we want to be an attractive employer offering existing and future office-based employees the opportunity to work where they can do their job best.
    Magnus Lundbäck, Executive Vice President Human Resources and Sustainability at Getinge
    In times when travel and in-person contact is very limited, the possibility to step into our virtual hospital fills a crucial gap.
    Jeanette Hedén Carlsson, EVP Communication & Brand Management at Getinge.
    This partnership is an example of the extended scope of our sustainability, innovation and customer centricity and our dedication for driving Getinge to the forefront within these research areas. Ultimately, the knowledge and experience we gain can help us save more lives together with our customers
    Magnus Lundbäck, Executive Vice President Human Resources & Sustainability.
    The commitment to the Science Based Target initiative is a natural next step for us. This is a good way to increase transparency on our commitment and progress. Getinge is aiming at becoming a CO₂ neutral company and has set-up dedicated activities to achieve our goal.
    Magnus Lundbäck, Executive Vice President Sustainability at Getinge
    With the investment in Merrimack we are looking at double the installed production capacity of DPTE-BetaBag®
    Harald Castler, Executive Vice President Life Science at Getinge
    We have continued to support health care, and the pharmaceutical companies that are rapidly developing and manufacturing COVID-19 vaccines. We also achieved our full-year target of delivering 26,000 advanced ICU ventilators, and the demand for our ECMO therapy products remains high.
    Mattias Perjos, President & CEO at Getinge
    With the acquisition of Quadralene, we will bring additional value and support to our customers in their mission to reduce hospital acquired infections
    Stéphane Le Roy, President Surgical Workflows at Getinge.
    While measuring continuously and non-invasively, NICCI provides a complete picture of the patient’s individual hemodynamic status – ensuring the medical staff that they never miss a beat
    Clemens Brühl, Head of Product Management Advanced Patient Monitoring at Getinge
    Especially now, when fighting with the COVID-19 pandemic, health care organizations are facing strong operational and financial challenges. Sterilization units have to reprocess surgical instruments in a flawless manner in order to manage an increasing backlog of surgeries.
    Stéphane Le Roy, President Surgical Workflows at Getinge
    The site produces approximately 230,000 units per year, which is estimated to support saving 500 lives per day
    Jocelyn Lebrun, Managing Director Getinge La Ciotat
    We are continuing to deepen our partnerships with hospitals and pharmaceutical companies around the world to combat COVID-19 and in the third quarter we delivered more advanced ICU ventilators than we normally do in a whole year
    Mattias Perjos, President & CEO Getinge
    We've gone from a mode of ventilation where you were breathing for the baby to one now where we can breathe with the baby as well
    Sabina Checketts, neonatal doctor
    In addition to helping maintain the diaphragm's tone, the synchrony of a NAVA ventilator means patients don't fight against the ventilator
    Miray Kärnekull, Medical Director at Getinge
    This large multi-center independent trial supports that NAVA has significant positive clinical effects for adult patients in intensive care units (ICU). The study showed that through the use of NAVA, the days on mechanical ventilation could be reduced from 12 to 8 days, a four-day reduction or close to 35% which is quite a remarkable improvement with many positive consequences. Fewer days in the ICU also translates to a significantly improved health economy, enabling hospitals to free up precious ICU beds and resources
    Jens Viebke, President Acute Care Therapies at Getinge
    We are very proud to be part of AIMES. The clear focus on societal benefits will generate new products that can help medical teams all over the world save more lives at the same time as they emphasize Sweden’s competitiveness within medical science and engineering
    Harald Castler, President Life Science at Getinge
    We encourage lifelong learning and are proud to be collaborating with Universeum in raising interest in technology, science and sustainable societal development. We can contribute important knowledge in the area of creating a sustainable, productive healthcare system
    Mattias Perjos, President & CEO at Getinge.
    Our aim is to help hospitals make ICU bedsides quieter by safely moving the alarms outside patient rooms
    David Pitts, Clinical SME, Integrated Therapy Solutions Getinge.
    We want to support the important work the Foundation for Queen Silvia Children’s Hospital does to bring joy into the everyday lives of children and young people who are dealing with various illnesses
    Magnus Lundbäck, Executive Vice President Human Resources & Sustainability at Getinge
    FDA 510(k) clearance of Getinge’s Flow-e and Flow-c allows us to complete the portfolio of Flow anesthesia machines and offers innovative solutions with personalized anesthesia for high aquity patients in the large and expansive US marketplace.
    Eric Honroth, President of North America at Getinge
    To help health care providers restart their surgical activity, we looked at how we can utilize our miles of data and knowledge on surgery planning. We now offer a solution that is scalable, easy to deploy, and that offers quick results for staff and patients
    Matthias Rath, Director Product Management & Business Development OR Solutions
    During this year’s second quarter, we report a continued strong order intake and net sales of advanced ICU ventilators and ECMO therapy products for hospitals and Sterile Transfer products for the pharmaceutical industry
    Mattias Perjos, President & CEO
    We are happy to be able to help clinicians in their endeavor to save lives by adding an additional ventilator to our product offering in the US market
    Elin Frostehav, Vice President Critical Care at Getinge
    With Maquet Moduevo Bridge we are going horizontal. It’s ideal for rooms with low ceilings and can handle large units since they can be placed next to each other to avoid losing space
    Stephane Tabillon, Product Manager
    Patient safety starts in the CSSD, as it is crucial for any hospital that sterile instruments are received by the end user in a safe and timeous manner. With our new indicators, it takes only 20 minutes to ensure a crucial element of patient safety in steam and hydrogen peroxide processes.
    Cindy Graham, Senior Director Consumables
    The project aims at helping health care facilities to reduce the number of health care associated infections that can occur during operations
    Jonas Andersson, Vice President Global Product Management, Infection Control at Getinge
    We have a long history in New Jersey and this investment solidifies Getinge’s strong commitment to New Jersey and supports leadership training and knowledge sharing with our customers
    Eric Honroth, President Getinge North America
    The quarter was dominated by the COVID-19 pandemic and the huge need for advanced ventilators and ECMO therapy at intensive care units around the world. Our leading global positions in these fields contributed to a 47% organic order growth
    Mattias Perjos, President & CEO Getinge
    We continue to ramp up to be able to respond to the increasing demand from our customers. We work closely with our sub-contractors and the ramp up is of course pending availability of supply parts.
    Elin Frostehav, Vice President Critical Care at Getinge
    “This is very important for us in order to secure continued deliveries of our products into the EU market and into other markets dependent on the CE-mark"
    Mikael K Johansson, Senior Director Program Office Acute Care Thearapies & EU MDR at Getinge
    “Our organic sales growth continued in the fourth quarter and it was particularly good to see the strong performance of our three largest markets – the US, China and Germany,” says Mattias Perjos, President & CEO at Getinge. ”We improved the margins and the cash flow both in the quarter and for the full year, and the balance sheet was strengthened.”
    Mattias Perjos, President & CEO
    “Sustainability is a top priority and something we see as an integral part of Getinge, and we are of course very honored to receive this award. We will continue our work and progress to contribute to a better society”
    Magnus Lundbäck, Executive Vice President Human Resources & Sustainability at Getinge
    “Applikon Biotechnology has a strong portfolio of world class bioreactor solutions which will be a positive addition to Getinge’s existing offer towards the biopharma segment, the fastest growing area within Life Science”, says Mattias Perjos, President & CEO Getinge. “This deal further broadens our position within solutions for efficient, safe and contamination-free research and production processes.”
    Mattias Perjos, President & CEO Getinge
    We, at Getinge Group, are committed to partnering in training with the medical community and therefore very pleased about our ongoing partnership with VASCULAR INTERNATIONAL. Both organizations understand the importance of providing the appropriate training and guidance to surgeons early on in their medical careers. These workshops allow not only hands-on experience on training models but also provide the participants with the opportunity to network and build relationships with medical experts moving forward.
    Markus Stirner-Schilling
    Pick a time period -
    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top